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Induction of interleukin-8 preserves the angiogenic
response in HIF-1a–deficient colon cancer cells
Yusuke Mizukami1, Won-Seok Jo1, Eva-Maria Duerr1, Manish Gala1, Jingnan Li1, Xiaobo Zhang1,
Michael A Zimmer2, Othon Iliopoulos2, Lawrence R Zukerberg3, Yutaka Kohgo4, Maureen P Lynch5,
Bo R Rueda5 & Daniel C Chung1
Hypoxia inducible factor-1 (HIF-1) is considered a crucial
mediator of the cellular response to hypoxia through its
regulation of genes that control angiogenesis1–4. It represents
an attractive therapeutic target5,6 in colon cancer, one of
the few tumor types that shows a clinical response to
antiangiogenic therapy7. But it is unclear whether inhibition
of HIF-1 alone is sufficient to block tumor angiogenesis8,9.
In HIF-1a knockdown DLD-1 colon cancer cells (DLD-1HIF-kd),
the hypoxic induction of vascular endothelial growth factor
(VEGF) was only partially blocked. Xenografts remained highly
vascularized with microvessel densities identical to DLD-1
tumors that had wild-type HIF-1a (DLD-1HIF-wt). In addition to
the preserved expression of VEGF, the proangiogenic cytokine
interleukin (IL)-8 was induced by hypoxia in DLD-1HIF-kd but
not DLD-1HIF-wt cells. This induction was mediated by the
production of hydrogen peroxide and subsequent activation of
NF-jB. Furthermore, the KRAS oncogene, which is commonly
mutated in colon cancer, enhanced the hypoxic induction of
IL-8. A neutralizing antibody to IL-8 substantially inhibited
angiogenesis and tumor growth in DLD-1HIF-kd but not DLD-
1HIF-wt xenografts, verifying the functional significance of this
IL-8 response. Thus, compensatory pathways can be activated
to preserve the tumor angiogenic response, and strategies
that inhibit HIF-1a may be most effective when IL-8 is
simultaneously targeted.
We subcutaneously injected DLD-1 cells, which contained either
wild-type HIF-1a or HIF-1a stably knocked down by siRNA10
(DLD-1HIF-wt or DLD-1HIF-kd, respectively), into CD1 nude mice.
Four weeks after inoculation, tumor volumes and weights were
significantly lower in DLD-1HIF-kd tumors (Fig. 1a,b), indicating an
important role for HIF-1 in tumor growth in vivo. We confirmed this
finding in an independent colon cancer cell line, Caco2 (Supplemen-
tary Fig. 1 online). Large necrotic areas were much more prevalent in
DLD-1HIF-wt xenografts (Fig. 1c). Furthermore, a prominent inflam-
matory infiltrate composed predominantly of neutrophils was
observed only in DLD-1HIF-kd xenografts (Fig. 1c). Although there
were larger areas of necrosis in DLD-1HIF-wt xenografts, the cross-
sectional surface area of non-necrotic viable tumor was still signifi-
cantly greater when compared to DLD-1HIF-kd xenografts (0.33 cm2
versus 0.16 cm2, respectively, P¼ 0.025). Thus, the difference in size of
the tumors cannot be entirely attributed to the larger area of necrosis
in the DLD-1HIF-wt tumors. A persistent silencing effect of the HIF-1a
siRNA construct was confirmed in vivo (Fig. 1d).
There was a significant decrease in the Ki-67 labeling index in
DLD-1HIF-kd xenografts (41.3 ± 3.2% in DLD-1HIF-wt tumors versus
27.4 ± 2.6% in DLD-1HIF-kd tumors; Po 0.01), suggesting that HIF-
1a regulates cellular proliferation in vivo. We calculated the apoptotic
index by counting TUNEL-positive cells in non-necrotic areas. We
observed a small but statistically significant difference in the apoptotic
index between the two groups (3.2 ± 0.53% in DLD-1HIF-wt tumors
versus 1.9 ± 0.42% in DLD-1HIF-kd tumors; P o 0.05), but this
difference is unlikely to counterbalance the considerable difference in
proliferation rates.
When we incubated DLD-1HIF-kd cells under hypoxic conditions
(1% O2) in vitro, we observed only a 25% reduction (P ¼ 0.11) in
the induced levels of VEGF mRNA and protein (Fig. 1e). In the
DLD-1HIF-kd xenografts, VEGF mRNA and protein levels were also
induced (Fig. 1f), though not to the same extent observed in vitro.
Compared to the DLD-1HIF-wt xenografts, VEGF mRNA levels were
51% lower (P ¼ 0.028) and protein levels were 52% lower (P ¼
0.0024) in DLD-1HIF-kd xenografts. This persistent expression of VEGF
was not mediated by HIF-2a, as mRNA encoding HIF-2a and HIF-2a
protein levels were barely detectable in normoxic conditions and the
gene was not induced by hypoxia (Supplementary Fig. 2 online).
To specifically address whether hypoxia regulates VEGF in the
absence of HIF-1 in vivo, we identified hypoxic areas within the
tumor mass using Hypoxyprobe-1 (pimonidazole hydroxychloride).
There were large hypoxic regions surrounding the necrotic areas in the
center of the DLD-1HIF-wt tumors (Fig. 1g). In contrast, DLD-1HIF-kd
tumors showed only restricted regions of intratumoral hypoxia.
Double immunofluorescence showed that VEGF was preferentially
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expressed in the hypoxic areas of both DLD-1HIF-kd and DLD-1HIF-wt
xenografts (Fig. 1g).
It is possible that the difference in growth between the xenografts
resulted from impaired angiogenesis, potentially attributable to lower
levels of VEGF in DLD-1HIF-kd tumors. But immunostaining for the
endothelial cell marker CD31 showed abundant microvascular net-
works in all tumors (Fig. 1h). We observed no quantitative difference
in microvessel density (26.1 ± 6.3/field in DLD-1HIF-wt and 28.7 ± 8.6/
field in DLD-1HIF-kd xenografts), suggesting that high levels of HIF-1
may not be required to stimulate angiogenesis or maintain vessel
integrity in DLD-1 tumors.
Although upregulation of VEGF was preserved in DLD-1HIF-kd
xenografts, the absolute levels of VEGF were reduced. We therefore
determined whether other angiogenic factors may be induced in a
compensatory manner to maintain tumor vascularity in the absence of
HIF-1. cDNA microarray analysis identified genes that were upregu-
lated at least twofold by hypoxia but whose expression was attenuated
less than 30% when HIF-1 was silenced. VEGF was upregulated
fourfold in DLD-1HIF-wt cells by hypoxia, and this induction was
decreased only 10.6% by HIF-1 silencing (Supplementary Table 1
online). In addition, expression of the proangiogenic cytokine IL-8
was increased twofold in DLD-1HIF-kd cells cultured in hypoxic
conditions compared to DLD-1HIF-wt cells.
Hypoxia upregulated IL-8 mRNA 42.5-fold in DLD-1HIF-kd cells,
but there was no induction in DLD-1HIF-wt cells (Fig. 2a). Consistent
with this result, the level of IL-8 in the supernatant of DLD-1HIF-kd
cells was increased almost threefold compared to DLD-1HIF-wt cells.
We obtained similar results with previously established, independent
DLD-1HIF-kd clones10 (data not shown). Extracts from DLD-1HIF-kd
xenografts also showed significantly higher IL8 mRNA and protein
levels when compared to DLD-1HIF-wt tumors (Fig. 2b). IL-8 promo-
ter reporter constructs showed higher basal activity in DLD-1HIF-kd
cells (Fig. 2c), and there was further induction of promoter activity in
hypoxia that was not observed in the DLD-1HIF-wt cells. There was
also a 2.1-fold induction of the IL-8 promoter when HIF-1a was
transiently knocked down in parental DLD-1 cells, indicating this
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Figure 1 Growth of DLD-1HIF-kd cells in vivo. (a) Tumor volume and weight of DLD-1HIF-wt and DLD-1HIF-kd xenografts. *P o 0.05. (b) Gross appearance
of xenografts and excised tumors at 4 weeks. Scale bar, 5 mm. (c) H&E staining of resected tumors. Left scale bars, 1 mm; right scale bars, 50 mm.
(d) Immunoblotting for HIF-1a and Glut-1 in DLD-1HIF-kd xenografts. VEGF mRNA and protein levels in cultured DLD-1 cells (e) and in tumor xenografts
(f) were measured. (g) Intratumoral ‘hypoxia’ was detected by immunohistochemistry for Hypoxyprobe-1. Scale bar, 1 mm. Immunofluorescent staining for
VEGF (Texas red) and Hypoxyprobe-1 (FITC). Scale bar, 100 mm. (h) Immunohistochemistry for CD31 and quantification of microvessel density in DLD-1
xenografts. Scale bar, 100 mm.
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phenomenon was not an artifact of the stable transfection process. In
addition, expression of a constitutively active HIF-1a in which the
proline at position 564 was changed to an alanine in DLD-1 cells did
not induce the IL-8 promoter (1.01 ± 0.14-fold increase), indicating
that HIF-1 does not directly regulate IL-8 gene expression. This
hypoxic effect was not unique to DLD-1 cells. Knockdown of HIF-
1a in additional colon cancer cells (ColoHSR, SW 480 and HCT116),
pancreatic cancer cells (Panc-1, CAPAN-1), breast cancer cells (MDA-
MB-453) and lung cancer cells (HOP-92) showed a similar induction
of IL-8 in hypoxia (Supplementary Fig. 3 online). Finally, we
confirmed specificity of these siRNA constructs by observing expres-
sion of HIF-1a synonymous codon mutants (Supplementary Fig. 4
online). The absence of HIF-1 can therefore stimulate IL-8 on a
transcriptional level, and this is further enhanced in hypoxia.
NF-kB is a major regulator of IL-8. NF-kB reporter activity was
increased 151% (P o 0.01) in HIF-1a knockdown cells (Fig. 2d).
Western blotting (Fig. 2e) and immunohistochemistry (Fig. 2f) of
tissue xenografts showed that phosphorylation of the p65 subunit was
greater in DLD-1HIF-kd xenografts, suggesting that HIF-1 inhibition
does upregulate the NF-kB pathway in vivo. Densitometry of western
blots quantified a 2.0 ± 0.4-fold increase in the ratio of phosphory-
lated p65 to unphosphorylated p65 (P o 0.01). The hypoxic induc-
tion of the IL-8 promoter in DLD-1HIF-kd cells was significantly
downregulated by BAY 11-7082, a specific inhibitor of NF-kB11
(Fig. 2g). Thus, activation of the NF-kB pathway is important for
the induction of IL-8 in the absence of HIF-1.
We then speculated that HIF-1 inhibition may enhance the produc-
tion of hydrogen peroxide (H2O2), a reactive oxygen species (ROS) that
can activate NF-kB12,13. Hypoxic conditions can lead to the increased
production of ROS14,15, and scavenging of ROS is often achieved by
increased production of pyruvate16 that occurs when cells shift from
oxidative to glycolytic metabolism. This shift depends upon HIF-1a17.
DLD-1HIF-kd cells released more H2O2 in vitro, and hypoxia further
enhanced its production (Fig. 3a). Four distinct chemical inhibitors of
ROS production (N-acetyl-L-cysteine, pyrrolidinedithiocarbamate,
rotenone and diphenylene iodonium) each strongly blocked the
induction of NF-kB promoter activity by hypoxia in DLD-1HIF-kd
cells (Fig. 3b). Finally, exogenous administration of the long-acting
H2O2 analog, t-butyl hydroperoxide, stimulated the production of IL-8
in parental DLD-1 cells. This induction was inhibited by BAY 11-7082
(Fig. 3c), again showing that NF-kB mediates this effect of ROS.
In contrast to DLD-1HIF-kd cells, we did not observe hypoxic
induction of IL8 mRNA (Fig. 3d) and protein (data not shown) in
Caco2HIF-kd colon cancer cells10. Given that DLD-1 cells harbor the
Gly13Asp mutation in the KRAS oncogene (KRAS38g-a), whereas
Caco2 cells are wild-type (KRAS35g/35g), we speculated that oncogenic
KRAS may have a role in the hypoxic induction of IL-8 (ref. 18). When
we induced the expression of the Gly12Val KRAS mutation
(KRAS35g-t) in Caco2HIF-kd cells , hypoxia upregulated IL-8 mRNA
2.5-fold, whereas the effect was not observed in Caco2HIF-wt cells or in
Caco2HIF-kd cells exposed to hypoxia only (Fig. 3d). KRAS35t only
modestly induced IL-8 mRNA in Caco2HIF-kd cells in normoxic con-
ditions. Expression of KRAS35t in Caco2HIF-wt cells also upregulated the
IL-8 promoter, but this activation was more pronounced in Caco2HIF-kd
cells under conditions of hypoxia (Fig. 3e). BAY 11-7082 blocked the
induction of the IL-8 promoter by hypoxia and KRAS35t (Fig. 3e).
Exogenous expression of oncogenic KRAS may act supraphysio-
logically. Endogenous KRAS38a in DLD-1 cells was therefore silenced
by siRNA and this resulted in a 50% reduction of KRAS protein levels,
consistent with a silencing effect of the one mutant allele19. Knock-
down of KRAS38a attenuated the hypoxic induction of an NF-kB
reporter and IL8 promoter activity (Fig. 3f) as well as IL8 mRNA
levels (Fig. 3g) in DLD-1HIF-kd but not in DLD-1HIF-wt cells. These
observations were confirmed in the Panc-1 pancreatic and PC3
prostate cancer cell lines, indicating the broader importance of
KRAS on this alternative regulation of IL-8 (Supplementary Fig. 5
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Figure 2 Knockdown of HIF-1 facilitates the induction of IL-8 by NF-kB during hypoxic conditions. IL8 mRNA and protein levels in (a) cultured DLD-1 cells
and (b) DLD-1 xenografts. (c) IL8 promoter activity during hypoxia in DLD-1HIF-kd and DLD-1HIF-wt cells. (d) NF-kB reporter activity in hypoxic conditions in
DLD-1HIF-kd cells. (e) Immunoblotting for NF-kB, p65 subunit and Ser536-phosphorylated p65 (p-p65), in DLD-1 tumor lysates. (f) Immunohistochemistry
for phosphorylated p65 in DLD-1 xenografts (shown as Texas Red). Scale bar, 50 mm. (g) Effect of NF-kB inhibition on IL8 promoter activity with
BAY 11-7082.
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online). Furthermore, we observed the stimulatory effect of oncogenic
KRAS on NF-kB in hypoxic conditions or in the presence of ROS
(Figs. 3d,h). Collectively, these studies indicate that IL-8 can be
induced in hypoxia through the activation of NF-kB in the absence
of HIF-1, and that oncogenic KRAS can further stimulate NF-kB in
hypoxic conditions to upregulate this alternative angiogenic pathway.
Finally, we sought to determine the functional significance of
IL-8 production in HIF-1–deficient tumors. The observation that
DLD-1HIF-kd xenografts showed a marked inflammatory infiltrate
(Fig. 1c) was consistent with a functional role for IL-8, a potent
neutrophil chemokine18. Intraperitoneal administration of the IL-8
neutralizing antibody MAB208 resulted in complete regression of
25% of DLD-1HIF-kd xenografts, and among the other detectable
DLD-1HIF-kd tumors, there was a 61.3% reduction in tumor volume
(P o 0.01) and 61.8% reduction in tumor weight (P o 0.01)
compared to tumors treated with control IgG (Fig. 4a,b). In contrast,
there was only a 24.8% (P ¼ 0.28) and 15.6% (P ¼ 0.35) reduction in
tumor volume and weight, respectively, in DLD-1HIF-wt xenografts.
Although treatment with MAB208 resulted in a decrease in the Ki-67
labeling index and increase in apoptosis in the DLD-1HIF-kd xenografts
(Fig. 4c), in vitro studies showed that MAB208 did not directly inhibit
tumor cell growth (Fig. 4d). Rather, treatment with MAB208 resulted
in a considerable inhibition of angiogenesis. The microvessel density
in DLD-1HIF-kd xenografts was reduced 46.5% (Po 0.001) compared
to a 14.5% reduction (P ¼ 0.11) in DLD-1HIF-wt xenografts (Fig. 4e).
Confocal microscopy of tumor sections after lectin perfusion verified
that vascular integrity was compromised in DLD-1HIF-kd xenografts
treated with MAB208 (Fig. 4e). In addition to reduced vessel number,
the vessels were markedly narrowed and fragmented. Specifically, the
mean vessel diameter fell from 22.4 mm to 5.9 mm (P ¼ 0.0002) when
we treated DLD-1HIF-kd xenografts with MAB208, but there was no
change in the DLD-1HIF-wt xenografts (26.5 mm versus 24.8 mm with
MAB208; not significant). Neutralization of both IL-8 and VEGF in
DLD-1HIF-kd xenografts had an additive effect on the inhibition of
tumor growth (Fig. 4f), showing that each factor can regulate
tumorigenesis independently.
In summary, we have shown that HIF-1a deficiency in colon cancer
cells can inhibit proliferation and overall growth, but not angiogenesis.
There are conflicting reports of the role of HIF-1 in tumor cell
proliferation. Hif1a–/– embryonic stem cell–derived teratocarcinomas
show reduced as well as increased growth2,20. Among human tumors,
overexpression of HIF-1a has been associated with improved survival
in individuals with head and neck cancers21 and HIF-1 can inhibit the
growth of renal carcinoma cells22. This may be mediated through the
induction of the cell-cycle inhibitors p21 and p27 (ref. 23). It has been
speculated that HIF-1 may have intrinsic functions to either promote
or inhibit tumor growth that depends upon the cellular context24. The
preservation of angiogenesis in our model can be explained by
persistent expression of VEGF as well as induction of the proangio-
genic factor, IL-8. IL-8 was stimulated by ROS-mediated activation of
NF-kB, and this was enhanced by oncogenic KRAS. Neutralization
of IL-8 in HIF-1–deficient tumors led to a substantial inhibition of
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Figure 3 Increased production of ROS in HIF-knockdown cells expressing KRAS. (a) Increased
production of H2O2 in DLD-1
HIF-kd cells as measured by Amplex Red (left) and DCF
fluorescence (right). (b) Effect of inhibitors of hydrogen peroxide production, N-acetyl-L-cysteine
(NAC), pryrolidinedithiocarbamate (PDTC), rotenone (ROT) and diphenylene iodonium (DPI)
on induction of NF-kB reporter activity by hypoxia. *P o 0.01. (c) Induction of IL8 gene
expression by t-butyl hydroperoxide (t-BH) and inhibition by 5 mM BAY 11-7082. (d) Synergistic
effect of hypoxia and KRAS35t on IL-8 induction in Caco2HIF-kd cells. (e) Induction of IL8
promoter activity by KRAS35t and hypoxia and inhibition by BAY 11-7082. (f) NF-kB reporter
activity (left) and IL8 promoter activity (right) after siRNA-mediated silencing of endogenous
mutant KRAS. (g) IL8 mRNA levels in DLD-1HIF-kd cells after siRNA-mediated silencing of
endogenous mutant KRAS. (h) Effect of KRAS35t and 40 mM t-butyl hydroperoxide (t-BH) on
NF-kB reporter activity in Caco2 cells.
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angiogenesis and tumor growth. Studies of lung cancer cells harboring
a KRAS mutation have also shown a pivotal role for IL-8 in tumor
angiogenesis25. Collectively, these findings highlight the complex role
of HIF-1a in colorectal tumorigenesis, the diversity of pathways used
by tumors to stimulate angiogenesis, and the potential for combina-
tion antiangiogenic regimens that target both HIF-1 and IL-8.
METHODS
Cell lines. We stably transfected DLD-1 and Caco2 cells (ATCC) with HIF-1a–
specific siRNA constructs (pSuper.retro, OligoEngine), pSR.HIF-1a1470 or
pSR.HIF-1a2192 (ref. 10). Three independent DLD-1 clones stably expressing
pSR.HIF-1a1470 and two independent clones expressing pSR.HIF-1a2192
showed similar responses to hypoxia with respect to induction of NF-kB and
IL-8. In a pilot xenograft study, growth, microvascular density, VEGF and IL-8
levels were similar between a pSR.HIF-1a1470 clone and pSR.HIF-1a2192 clone.
Hypoxic conditions (1% O2) were achieved with a sealed hypoxia chamber
(Billups-Rothenberg) in serum-free UltraCulture medium (Cambrex)10. We
performed transient transfections using Lipofectamine 2000 (Invitrogen).
Plasmid constructs. The IL-8 reporter26, NF-kB reporter and phr-GFP-KRAS35t
plasmids have been described27. We performed site-directed mutagenesis
to obtain the phr-GFP-KRAS38a construct. We constructed pSuper.Kras38a
(pSR.Kras38a) by subcloning the sequence 5¢-GGAGCTGGTGACGTAGGCA-3¢.
For control siRNA, pSR.cont, we used the sequence 5¢-GCGCGCTTTGTAG
GATTCG-3¢ (ref. 28). For mutations in KRAS, we used a numbering system in
which position 1 is the A of the initiator ATG codon. KRAS38a results in a
Gly13Asp mutation and KRAS35t results in a Gly12Val mutation.
Transfections and reporter assays. We cotransfected 0.1–0.2 mg of reporter
constructs with 2 ng of pRL-CMV (Promega) and measured luciferase activity
with the Dual Luciferase Reporter Assay System (Promega). We used pRL-null,
a promoter-less Renilla construct, when we cotransfected cells with a KRAS
expression vector29. We calculated the relative luciferase activity as the ratio of
firefly/Renilla luciferase activity. The level of ‘hypoxic induction’ was the ratio
between the relative luciferase activity in hypoxia to that in normoxia.
Xenograft tumor model. We injected 2  106 cells subcutaneously into the
flanks of 6–8-week-old CD1 female nude mice (six mice per arm). We
measured tumors with calipers and calculated volume as (length  width2)
 0.5. We intraperitoneally administered neutralizing antibody to IL-8
(MAB208, clone 6217.111; R&D Systems) and/or VEGF (MAB293, R&D
Systems) when tumors reached 5 mm. We injected 100 mg of MAB208 and/
or 25 mg of MAB293 on days 7, 9, 11, 14, 16, 18, 21 and 23, before mice were
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Figure 4 Role of IL-8 in tumor angiogenesis in vivo. Tumor
volume (a) and weight (b) of DLD-1HIF-wt and DLD-1HIF-kd
xenografts after treatment with neutralizing antibody to IL-8,
MAB208 (*P o 0.01, DLD-1HIF-kd + IgG versus DLD-1HIF-kd
+ MAB208). Scale bars, 5 mm. There was no change in the
percentage of non-necrotic viable tumor with MAB208
treatment (DLD-1HIF-wt: 69.8% versus 69.9%; DLD-1HIF-kd:
87.8% versus 83.9%, IgG versus MAB208, not significant).
(c) Ki-67 labeling and TUNEL indices in MAB208-treated
xenografts. (d) Growth of DLD-1 cells in the presence of
MAB208 under hypoxic conditions. (e) Blood vessels
visualized by CD31 immunohistochemistry (upper; scale bar, 100 mm) and lectin perfusion (lower; scale bar, 50 mm). Narrow and fragmented vessels are
present in DLD-1HIF-kd + MAB208. (f) Growth of DLD-1HIF-kd xenografts when treated with a neutralizing VEGF antibody (MAB293) and/or a neutralizing
antibody to IL-8 (MAB208). In these xenografts, the percentage of viable non-necrotic tumor fell slightly to 74.7% from 87.8% in mice that received control
antibody only (P ¼ 0.1).
L E T TERS
996 VOLUME 11 [ NUMBER 9 [ SEPTEMBER 2005 NATURE MEDICINE
©
20
06
 
N
at
ur
e 
Pu
bl
is
hi
ng
 G
ro
u
p 
 h
ttp
://
w
w
w.
n
at
ur
e.
co
m
/n
at
ur
em
ed
ic
in
e
killed at day 25. To assess hypoxic regions, we intraperitoneally injected mice
with 60 mg/kg pimonidazol hydrochloride (Hypoxyprobe-1, Chemicon), 1.5 h
before killing. To visualize functional tumor microvessels, we intravenously
injected 100 mg FITC-labeled tomato lectin (Vector Laboratories), and perfused
the hearts of the mice with 4% paraformaldehyde. This protocol was approved
by the Animal Care and Use Committee of the Massachusetts General Hospital.
Immunohistochemistry. We treated 5-mm sections from fresh frozen tumors
with acetone and blocked endogenous peroxidase with 3% H2O2. We incubated
the sections with a CD31-specific antibody, MEC13.3 (1:50; Pharmingen),
overnight at 4 1C. We counted blood vessels in 5–10 random viable fields
(magnification, 200). To detect tumor hypoxia, we treated formalin-fixed
sections with 0.01% pronase and incubated them with Hypoxpyrobe-1–specific
antibody Mab1 (1:50; Chemicon). For other immunohistochemical studies, we
fixed xenograft tissues in 10% neutral buffered formalin. We performed
TUNEL staining with the ApoAlert DNA fragmentation detection kit (Clon-
tech). We performed Ki-67 staining with the MIB-1 antibody (1:100; DAKO)
and performed staining for Ser563-phosphorylated p65 (1:50; Cell Signaling).
Real-time PCR assay. We extracted RNA using the RNeasy kit (Qiagen) and
performed quantitative reverse transcription PCR using the SuperScript III
platinum Two-Step qRT-PCR Kit (Invitrogen). Primer sequences for VEGF, IL8
and 18S RNA are available upon request. We used a fluorogenic SYBR Green
and MJ research detection system for real-time quantification.
Immunoblotting. We performed immunoblot analysis for HIF-1a (clone 54,
1:250; Transduction Laboratories), HIF-2a (1:250, Novus), Glut-1 (GT-11A,
1:1000; Alpha Diagnostic International), VEGF (Ab-2, 1:40; Calbiochem),
Ser563-phosphorylated p65 and total NF-kB p65 (1:1,000; both Cell Signaling),
KRAS (F234, 1:200; Santa Cruz) and b-actin (AC15, 1 mg/ml; Sigma) after SDS-
PAGE and electrophoretic transfer to polyvinylidene fluoride membranes10.
ELISA. We assayed the levels of VEGF and IL-8 protein in conditioned medium
and tissue lysates using specific ELISA kits (Quantikine, R&D Systems).
Microarray analysis. We performed sample preparation and processing pro-
cedures as described in the Affymetrix GeneChip Expression Analysis Manual.
We hybridized the labeled cRNA samples to the complete Affymetrix human
U133 GeneChip set (HG-U133A).
Hydrogen peroxide studies. We measured H2O2 using the Amplex Red
Hydrogen peroxide Assay Kit and the CM-H2DCFDA reagent (both from
Molecular Probes). We exposed cells to hypoxia for 10 h, and then switched
culture medium to Krebs-Ringer phosphate buffer30 containing 100 mM Amplex
Red reagent and 0.2 U/ml horseradish peroxidase. After additional incubation in
hypoxia for 1 h, we measured fluorescence in 96-well plates using Spectra MAX
GEMINI XS microplate fluorometer (Molecular Devices). We also incubated
cells with 10 mM CM-H2DCFDA for 30 min in RPMI without phenol red. We
measured fluorescence in 96-well plates and normalized values to cell number.
We added 20 or 40 mM t-butyl hydroperoxide (Sigma) to the culture media of
DLD-1 cells every 30 min for 6 h and measured IL8 mRNA using qRT-PCR.
Statistical analysis. We performed statistical analyses with a two-tailed,
unpaired Student t-test.
Note: Supplementary information is available on the Nature Medicine website.
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CORRIGENDUM: Combating diabetes and obesity in Japan
Y Yazaki & T Kadowaki
Nat. Med. 12, 73–74 (2006)
In Box 1, “(BM ≥125)” should read “(BMI ≥25).”
CORRIGENDUM: ATM regulates target switching to escalating doses of
radiation in the intestines
H-J Ch’ang, J G Maj, F Paris, H R Xing, J Zhang, J-P Truman, C Cardon-Cardo, A Haimovitz-Friedman, R Kolesnick & Z Fuchs
Nat. Med. 11, 484–490 (2005)
In Figure 2a, ceramide levels at 8 and 12 h after 16 Gy should have read 102 ± 10 and 118 ± 10 percent of control, respectively, and s.e.m. values 
for the remaining points should be multiplied by a factor of 2.6.
CORRIGENDUM: Induction of interleukin-8 preserves the angiogenic 
response in HIF-1α–deficient colon cancer cells
Y Mizukami, W-S Jo, E-M Duerr, M Gala, J Li, X Zhang, M A Zimmer, O Iliopoulos, L R Zukerberg, Y Kohgo, M P Lynch, B R Rueda & 
D C Chung
Nat. Med. 11, 992–997 (2005)
In Figure 3d, the labels for the cell lines are incorrect. Instead of DLD-1/HIF-wt and DLD-1/HIF-kd, the labels should be Caco2/HIF-wt and 
Caco2/HIF-kd, respectively.
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